GOSS News and Press, Gossamer Bio Inc. From 12/13/22

Short Squeeze Penny Stocks To Watch Today You’ve got your strategy laid out, you know you want to make money with penny stocks ; now what? It might seem as easy as throwing a dart at a dart board at times. But 2022 has been one of the more challenging years to trade like that. ...

Summary Gossamer Bio, Inc.'s lead candidate - Seralutinib, indicated for Pulmonary Arterial Hypertension - met its primary endpoint in the Phase 2 TORREY study. Nevertheless, investors dumped the stock - due to Seralutinib's perceived inferiority to Merck's Sotatercept. On a 6-minut...

Clinical stage biotech Gossamer Bio ( NASDAQ: GOSS ) continued to trade lower in the premarket trading Wednesday as Barclays downgraded the stock to Equal Weight from Overweight in reaction to the company’s Phase 2 data for seralutinib, a candidate for pulmonary arterial hypertensi...

Gossamer Bio ( NASDAQ: GOSS ) announced Phase 2 data for its candidate for pulmonary arterial hypertension (PAH) seralutinib on Monday, sending its shares to an all-time low in a selloff Piper Sandler identified as an overreaction. Topline data from the TORREY study showed that a dry ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: ToyW / Shutterstock Taiwan Semiconductor (NYSE: TSM ) stock is on the move Tuesday as investors prepare for President Joe Biden to visit the company’s Arizona plant . The U.S. President is planning...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gossamer Bio (NASDAQ: GOSS ) is one of the top-trending tickers on social media today, and its shares are plunging more than 70%. The company announced that a trial of its drug for hypertension, seralutinib, had met the p...

- Primary Endpoint, Change in PVR at Week 24, Met with P-Value of 0.0310 - - Secondary Endpoint, Change in 6MWD, Numerically Favored Seralutinib - - Statistically Significant Improvements Observed in NT-proBNP and ECHO Measures of Cardiac Structure and Function - - Consist...

Gossamer Bio press release ( NASDAQ: GOSS ): Q3 GAAP EPS of -$0.65 misses by $0.01 . Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of September 30, 2022, were $304.4 million. Research and Development (R&D)...

- Seralutinib Phase 2 TORREY Study on track for topline readout in second half of November or first half of December - - $304 million in cash, cash equivalents & marketable securities, as of September 30, 2022 - Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage...

Gossamer Bio Inc ( NASDAQ: GOSS ) is in the green on Thursday after a Goldman Sachs analyst said the stock is ready for another huge move to the upside. Gossamer Bio stock could rally to $22 On Thursday, Paul Choi assumed coverage of this “under the radar” biop...